Research review priorities
Supplement research priorities
These are research priorities, not recommendations. We selected decisions where public interest, plausible benefit, evidence maturity, and safety stakes make a careful synthesis especially useful.
- priority dossiers
- 148
- claim-level questions
- 444
- study extraction underway
- 148
01 / PRIORITY
How priorities were selected
Priority reflects relevance to healthy aging, frequency of real-world use, maturity of human evidence, the cost of a wrong decision, and the need to separate a valid narrow use from broader marketing claims. It does not rank efficacy or imply that everyone should take the product.
02 / EXTRACTION
What happens next
For every question, we screen the PubMed candidate set, connect multiple publications from the same trial, extract population, dose, comparator, duration, outcomes, harms, and funding, then synthesize supportive, mixed, negative, and safety findings together.
Only screened studies enter audited study and participant totals. Search-result counts and the papers listed here as questions never become evidence by themselves.Lycopene
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Randomized prostate-cancer evidence does not improve PSA overall, and biomarker subgroups do not establish clinical outcomes.
Questions being reviewed
- Does lycopene affect prostate-cancer progression, treatment response, or survival rather than PSA alone?
- Do blood-pressure or lipid findings translate into cardiovascular benefit?
- What dose, food-versus-extract, gastrointestinal, bleeding, medicine, and pregnancy limits apply?
AREDS2 formula
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
The formula is condition- and risk-specific; primary AREDS2 additions were neutral and beta-carotene safety changes matter for smokers.
Questions being reviewed
- Which age-related macular degeneration stages and eye findings justify an AREDS2 formula?
- Which ingredient substitutions and zinc doses preserve benefit while reducing harm?
- What smoking, lung-cancer, zinc, copper, medicine, surgery, and ophthalmology-supervision limits apply?
Chromium picolinate
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Weight loss is small and non-robust, while diabetes evidence mixes chromium forms and lacks long-term clinical outcomes.
Questions being reviewed
- Does chromium picolinate produce clinically meaningful and durable weight loss?
- Does chromium picolinate improve glycemic outcomes beyond standard diabetes care?
- What kidney, liver, psychiatric, glucose-lowering medicine, pregnancy, and product-quality limits apply?
Cinnamon extract
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Pooled glycemic changes come with extreme heterogeneity, short duration, and uncertain species and product standardization.
Questions being reviewed
- Which cinnamon species and standardized extract improves HbA1c as an adjunct to diabetes care?
- Are glucose and lipid effects durable and linked to fewer diabetes complications?
- What coumarin, liver, bleeding, glucose-lowering medicine, surgery, pregnancy, and species limits apply?
Fenugreek
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Glycemic signals mix seeds, extracts, and add-on designs, while hard outcomes and long-term safety remain untested.
Questions being reviewed
- Which standardized fenugreek preparation meaningfully improves HbA1c alongside standard care?
- Do glucose or lipid changes reduce diabetes complications or medicine needs?
- What hypoglycemia, bleeding, allergy, gastrointestinal, surgery, pregnancy, and odor-related limits apply?
03 / SOURCES
Research standards
The review begins with federal evidence summaries and PubMed records, then moves to trial-level extraction. Product claims or another publisher’s evidence grade are not copied into the ledger.